Recent Highlights
All Stories for Eli Lilly
Eli Lilly's, Regeneron's antibody drugs against COVID-19 raise hopes of preventing infection, hospitalisation
• 4 years agoEli Lilly’s study of 1,035 outpatients recently diagnosed with COVID-19 revealed that only 2 percent needed hospitalisation on its drug.
What are monoclonal antibodies ? Why do we need them as well as a COVID-19 vaccine?
• 4 years agoThe FDA issued emergency use authorization for Eli Lilly’s monoclonal antibody while Regeneron is still awaiting the FDA’s green light for its antibody treatment.
Two COVID studies paused due to safety issues; Mumbai metro to resume from 19 Oct, India's tally crosses 72 lakh
Fp Staff • 4 years agoIndia’s coronavirus tally rose to 72,39,389 on Wednesday as the country reported 63,509 new infections in 24 hours. The country’s toll climbed by 730 to 1,10,586
Two Eli Lilly's COVID-19 studies testing remdesivir, experimental antibody therapy paused due to safety issues
• 4 years agoThe paused study, called ACTIV-3, started in August and aims to enrol 10,000 hospitalized COVID-19 patients in the United States, Denmark and Singapore.
Experimental antibody drugs like Regeneron's don't cure COVID-19, but seem promising treatment options
• 4 years agoTrump is among fewer than ten people given access to Regeneron's drug under compassionate use rules, without enrolling in a study.
Antibody drug could prevent COVID-19 hospitalizations, says Eli Lilly based on partial trial results
• 4 years agoThe drug may keep mild to moderately ill COVID-19 patients from hospitalized, a goal no current COVID-19 drug has managed to do.
Salaries at B-schools up 20%; Microsoft, Google, Snapdeal big recruiters
Fp Archives • 10 years agoThe placement season at business schools is witnessing a significant uptrend this year with rush of offers from domestic as well as international MNCs and average salaries rising by over 20 percent.
Pfizer, Teva reach deal to allow generic Viagra
Fp Archives • 11 years agoPfizer says it reached a settlement with Teva Pharmaceuticals that allows the generic drugmaker to launch a copycat version of its popular erectile dysfunction drug Viagra in 2017.